Logo image of ATXS

ASTRIA THERAPEUTICS INC (ATXS) Stock Fundamental Analysis

NASDAQ:ATXS - Nasdaq - US04635X1028 - Common Stock - Currency: USD

5.97  -0.27 (-4.33%)

After market: 5.97 0 (0%)

Fundamental Rating

3

ATXS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ATXS as it has an excellent financial health rating, but there are worries on the profitability. ATXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATXS had negative earnings in the past year.
In the past year ATXS has reported a negative cash flow from operations.
ATXS had negative earnings in each of the past 5 years.
ATXS had a negative operating cash flow in each of the past 5 years.
ATXS Yearly Net Income VS EBIT VS OCF VS FCFATXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

ATXS's Return On Assets of -34.81% is fine compared to the rest of the industry. ATXS outperforms 61.83% of its industry peers.
Looking at the Return On Equity, with a value of -37.35%, ATXS is in the better half of the industry, outperforming 72.58% of the companies in the same industry.
Industry RankSector Rank
ROA -34.81%
ROE -37.35%
ROIC N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ATXS Yearly ROA, ROE, ROICATXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATXS Yearly Profit, Operating, Gross MarginsATXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ATXS has been increased compared to 1 year ago.
ATXS has more shares outstanding than it did 5 years ago.
ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATXS Yearly Shares OutstandingATXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ATXS Yearly Total Debt VS Total AssetsATXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ATXS has an Altman-Z score of 6.60. This indicates that ATXS is financially healthy and has little risk of bankruptcy at the moment.
ATXS has a Altman-Z score of 6.60. This is amongst the best in the industry. ATXS outperforms 80.29% of its industry peers.
ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.6
ROIC/WACCN/A
WACCN/A
ATXS Yearly LT Debt VS Equity VS FCFATXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 17.39 indicates that ATXS has no problem at all paying its short term obligations.
With an excellent Current ratio value of 17.39, ATXS belongs to the best of the industry, outperforming 91.04% of the companies in the same industry.
A Quick Ratio of 17.39 indicates that ATXS has no problem at all paying its short term obligations.
ATXS's Quick ratio of 17.39 is amongst the best of the industry. ATXS outperforms 91.04% of its industry peers.
Industry RankSector Rank
Current Ratio 17.39
Quick Ratio 17.39
ATXS Yearly Current Assets VS Current LiabilitesATXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.08% over the past year.
EPS 1Y (TTM)32.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.22% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-57.62%
EPS Next 2Y-28.8%
EPS Next 3Y-19.96%
EPS Next 5Y10.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATXS Yearly Revenue VS EstimatesATXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATXS Yearly EPS VS EstimatesATXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATXS. In the last year negative earnings were reported.
Also next year ATXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATXS Price Earnings VS Forward Price EarningsATXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATXS Per share dataATXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ATXS's earnings are expected to decrease with -19.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.8%
EPS Next 3Y-19.96%

More info and screens

0

5. Dividend

5.1 Amount

ATXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (7/18/2025, 8:00:01 PM)

After market: 5.97 0 (0%)

5.97

-0.27 (-4.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners92.53%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap336.89M
Analysts85.33
Price Target29.71 (397.65%)
Short Float %6.42%
Short Ratio6.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.91%
Min EPS beat(2)-18.75%
Max EPS beat(2)56.57%
EPS beat(4)2
Avg EPS beat(4)7.66%
Min EPS beat(4)-18.75%
Max EPS beat(4)56.57%
EPS beat(8)3
Avg EPS beat(8)-0.93%
EPS beat(12)7
Avg EPS beat(12)3.86%
EPS beat(16)9
Avg EPS beat(16)-93.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.6%
PT rev (3m)9.91%
EPS NQ rev (1m)-2.63%
EPS NQ rev (3m)-21.12%
EPS NY rev (1m)-2.32%
EPS NY rev (3m)-12.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-2.37
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS5.13
TBVpS5.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.81%
ROE -37.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.39
Quick Ratio 17.39
Altman-Z 6.6
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
EPS Next Y-57.62%
EPS Next 2Y-28.8%
EPS Next 3Y-19.96%
EPS Next 5Y10.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.19%
EBIT Next 3Y-20.11%
EBIT Next 5Y-16.07%
FCF growth 1Y-117.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.4%
OCF growth 3YN/A
OCF growth 5YN/A